Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcuvail in NAFLD
NCT06256926Phase 2Completed
- Sponsor
- COD Research
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by COD Research. Primary endpoint: Change in NAFLD grading based on liver USG at 60 days. Started Jan 2021; status: completed.
Beyond the preview
Go deeper on NCT06256926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256926.